Goldman Sachs Group Inc Alpine Immune Sciences, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.75 - $41.6 $754,215 - $1.77 Million	42,491 Added 21.47%	240,435 $9.53 Million
Q4 2023 Feb 13, 2024	BUY	$8.54 - $20.22 $1.12 Million - $2.66 Million	131,499 Added 197.91%	197,944 $3.77 Million
Q3 2023 May 14, 2024	SELL	$10.13 - $13.98 $1.33 Million - $1.84 Million	-131,499 Reduced 66.43%	66,445 $760,000
Q3 2023 Nov 14, 2023	BUY	$10.13 - $13.98 $108,087 - $149,166	10,670 Added 19.13%	66,445 $760,000
Q2 2023 May 14, 2024	BUY	$6.84 - $11.91 $170,439 - $296,773	24,918 Added 80.75%	55,775 $573,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $170,439 - $296,773	24,918 Added 80.75%	55,775 $573,000
Q1 2023 May 14, 2024	BUY	$7.0 - $8.75 $2,576 - $3,220	368 Added 1.21%	30,857 $238,000
Q1 2023 May 11, 2023	BUY	$7.0 - $8.75 $2,576 - $3,220	368 Added 1.21%	30,857 $238,000
Q4 2022 May 14, 2024	BUY	$5.45 - $7.35 $35,697 - $48,142	6,550 Added 27.36%	30,489 $224,000
Q4 2022 Feb 13, 2023	BUY	$5.45 - $7.35 $35,697 - $48,142	6,550 Added 27.36%	30,489 $224,000
Q3 2022 May 14, 2024	SELL	$6.89 - $9.39 $130,751 - $178,194	-18,977 Reduced 44.22%	23,939 $172,000
Q3 2022 Nov 10, 2022	SELL	$6.89 - $9.39 $130,751 - $178,194	-18,977 Reduced 44.22%	23,939 $172,000
Q2 2022 May 14, 2024	SELL	$6.71 - $9.52 $1.04 Million - $1.48 Million	-155,028 Reduced 78.32%	42,916 $365,000
Q2 2022 Aug 15, 2022	BUY	$6.71 - $9.52 $134,642 - $191,028	20,066 Added 87.82%	42,916 $365,000
Q1 2022 May 16, 2022	BUY	$6.41 - $13.89 $60,709 - $131,552	9,471 Added 70.79%	22,850 $205,000
Q4 2021 Feb 14, 2022	BUY	$10.41 - $13.95 $139,275 - $186,637	13,379 New	13,379 $185,000

Others Institutions Holding ALPN

# of Institutions

Shares Held

56.2K

Call Options Held

Put Options Held

View Full List

About ALPINE IMMUNE SCIENCES, INC.

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

More about ALPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account